EP2286826A3 - Behandlung von Tumor-Metastasen und Krebs - Google Patents

Behandlung von Tumor-Metastasen und Krebs Download PDF

Info

Publication number
EP2286826A3
EP2286826A3 EP10009648A EP10009648A EP2286826A3 EP 2286826 A3 EP2286826 A3 EP 2286826A3 EP 10009648 A EP10009648 A EP 10009648A EP 10009648 A EP10009648 A EP 10009648A EP 2286826 A3 EP2286826 A3 EP 2286826A3
Authority
EP
European Patent Office
Prior art keywords
tumor
cancer
metastase
treatment
taurultam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10009648A
Other languages
English (en)
French (fr)
Other versions
EP2286826B1 (de
EP2286826A2 (de
Inventor
Paul H. Redmond
Rolf W. Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Publication of EP2286826A2 publication Critical patent/EP2286826A2/de
Publication of EP2286826A3 publication Critical patent/EP2286826A3/de
Application granted granted Critical
Publication of EP2286826B1 publication Critical patent/EP2286826B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP10009648.6A 2000-10-27 2001-10-29 Behandlung von Tumor-Metastasen und Krebs Expired - Lifetime EP2286826B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24340900P 2000-10-27 2000-10-27
EP01309157A EP1201247B1 (de) 2000-10-27 2001-10-29 Behandlung des metastasierenden Karzinoms der Niere
EP09009373.3A EP2108373B1 (de) 2000-10-27 2001-10-29 Behandlung von Tumor-Metastasen und Krebs

Related Parent Applications (4)

Application Number Title Priority Date Filing Date
EP01309157.4 Division 2001-10-29
EP09009373.3A Division EP2108373B1 (de) 2000-10-27 2001-10-29 Behandlung von Tumor-Metastasen und Krebs
EP01309157A Division EP1201247B1 (de) 2000-10-27 2001-10-29 Behandlung des metastasierenden Karzinoms der Niere
EP09009373.3 Division 2009-07-20

Publications (3)

Publication Number Publication Date
EP2286826A2 EP2286826A2 (de) 2011-02-23
EP2286826A3 true EP2286826A3 (de) 2012-12-19
EP2286826B1 EP2286826B1 (de) 2017-01-04

Family

ID=22918669

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10009648.6A Expired - Lifetime EP2286826B1 (de) 2000-10-27 2001-10-29 Behandlung von Tumor-Metastasen und Krebs
EP09009373.3A Expired - Lifetime EP2108373B1 (de) 2000-10-27 2001-10-29 Behandlung von Tumor-Metastasen und Krebs
EP01309157A Expired - Lifetime EP1201247B1 (de) 2000-10-27 2001-10-29 Behandlung des metastasierenden Karzinoms der Niere

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP09009373.3A Expired - Lifetime EP2108373B1 (de) 2000-10-27 2001-10-29 Behandlung von Tumor-Metastasen und Krebs
EP01309157A Expired - Lifetime EP1201247B1 (de) 2000-10-27 2001-10-29 Behandlung des metastasierenden Karzinoms der Niere

Country Status (8)

Country Link
US (1) US20020098164A1 (de)
EP (3) EP2286826B1 (de)
JP (4) JP2002332241A (de)
AT (1) ATE456377T1 (de)
AU (1) AU779362B2 (de)
CA (1) CA2360228C (de)
DE (1) DE60141194D1 (de)
ES (3) ES2340021T3 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CA2462564C (en) 2001-10-01 2012-07-10 Rhode Island Hospital Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
CN101528195B (zh) * 2006-09-07 2012-03-28 埃德盖斯特利希索恩化学工业股份公司 羟甲基转移剂在制备治疗骨癌的药物中的用途
BR112012030641B8 (pt) * 2010-06-01 2022-06-14 Geistlich Pharma Ag Usos e composições para terapia farmacêutica oral
ES2945712T3 (es) * 2016-03-18 2023-07-06 Geistlich Pharma Ag Método de tratamiento de cáncer de mama triple negativo
WO2020234830A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
US20220323452A1 (en) * 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000743A1 (en) * 1990-07-09 1992-01-23 Ed Geistlich Söhne Ag Für Chemische Industrie Use of taurolidine and/or taurultam for the treatment of tumours
EP1066830A2 (de) * 1999-06-04 2001-01-10 Ed. Geistlich Söhne Ag Für Chemische Industrie Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3506288A1 (de) * 1984-09-06 1986-03-13 Johannes 7900 Ulm Reinmüller Vorrichtung zum einlegen in wunden und wundhoehlen
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
ES2531547T3 (es) 1999-12-06 2015-03-17 Geistlich Pharma Ag Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000743A1 (en) * 1990-07-09 1992-01-23 Ed Geistlich Söhne Ag Für Chemische Industrie Use of taurolidine and/or taurultam for the treatment of tumours
EP1066830A2 (de) * 1999-06-04 2001-01-10 Ed. Geistlich Söhne Ag Für Chemische Industrie Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)

Also Published As

Publication number Publication date
DE60141194D1 (de) 2010-03-18
JP2015163628A (ja) 2015-09-10
EP2286826B1 (de) 2017-01-04
EP1201247A2 (de) 2002-05-02
EP1201247A3 (de) 2002-09-18
EP1201247B1 (de) 2010-01-27
ES2424011T3 (es) 2013-09-26
EP2108373B1 (de) 2013-07-17
CA2360228C (en) 2010-02-02
CA2360228A1 (en) 2002-04-27
AU779362B2 (en) 2005-01-20
AU8155001A (en) 2002-05-02
EP2108373A1 (de) 2009-10-14
JP2002332241A (ja) 2002-11-22
ES2340021T3 (es) 2010-05-28
JP2010043114A (ja) 2010-02-25
JP2017125050A (ja) 2017-07-20
ATE456377T1 (de) 2010-02-15
EP2286826A2 (de) 2011-02-23
ES2621172T3 (es) 2017-07-03
US20020098164A1 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
EP2286826A3 (de) Behandlung von Tumor-Metastasen und Krebs
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
GB0128108D0 (en) Therapeutic use
MY129809A (en) Quinazoline derivatives
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1426375A3 (de) Analgetische Spiroindolderivate
EP1600168A3 (de) Pyrrolidinacetamid-Derivat, allein oder kombiniert, zur Behandlung von ZNS-Störungen
CN1545409A (zh) 二苯乙烯类化合物在制备用于治疗和预防糖尿病或与逆转录病毒有关疾病的药物中用途
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
MXPA03010761A (es) Combinaciones farmaceuticas.
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
WO2003011117A3 (en) Methods and compositions for treating and preventing distal bowel lesions
HK1068606A1 (en) Novel aminobenzoephenones
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
CA2363973A1 (en) Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
WO2004018044A8 (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
BG105216A (en) Use of camptothecin derivatives , with reduced gastrointestinal toxicity
EP1304111A3 (de) Verwendung von Methylol-enthaltenden Verbindungen zur Behandlung von Brustkrebs
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
WO2002051388A3 (en) Treatment of inoperable tumors by stereotactic injection of microspheres
EP0760239A3 (de) Pyrrol-, Imidazol-, und indolderivate zur Verwendung in der Krebstherapie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1201247

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2108373

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/20 20060101AFI20121112BHEP

Ipc: A61P 35/00 20060101ALI20121112BHEP

Ipc: A61K 31/549 20060101ALI20121112BHEP

Ipc: A61K 31/541 20060101ALI20121112BHEP

17P Request for examination filed

Effective date: 20130612

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20131021

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161028

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1201247

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2108373

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 858590

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60150276

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 858590

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170104

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2621172

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170104

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170504

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170104

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60150276

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170104

26N No opposition filed

Effective date: 20171005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170104

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171029

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171031

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171029

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20181019

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181019

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20181123

Year of fee payment: 18

Ref country code: FR

Payment date: 20181023

Year of fee payment: 18

Ref country code: GB

Payment date: 20181019

Year of fee payment: 18

Ref country code: IT

Payment date: 20181024

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170104

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60150276

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20191101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191029

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191029

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191030